2025

Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma
Götze J, Meißner K, Pereira-Veiga T, Belloum Y, Schneegans S, Kropidlowski J, Gorgulho J, Busch A, Honselmann K, Schönrock M, Putscher A, Peine S, Nitschke C, Simon R, Spindler V, Izbicki J, Hackert T, Bokemeyer C, Pantel K, Uzunoglu F, Sinn M, Wikman H
J EXP CLIN CANC RES. 2025;44(1):14.

Red blood cell-tumor cell interactions promote tumor cell progression
Pereira-Veiga T, Yáñez-Gómez C, Pekkarinen A, Abuín C, Blechner C, González-Conde M, Mess C, Vidal-Y-Sy S, Moustafa A, Siebels B, Dávila-Ibáñez A, Cabezas-Sainz P, Santos M, Sánchez L, Gorgulho J, Götze J, Meißner K, Cueva J, Palacios P, Cortegoso A, Curiel T, Rodríguez C, Carmona M, León-Mateos L, Abalo A, Muinelo-Romay L, Peine S, Schmidt M, Heuer-Olewinski N, Reck M, Abdo M, Lamszus K, Bauer A, López-López R, Pantel K, Windhorst S, Wikman H, Costa C
J EXP CLIN CANC RES. 2025;44(1):134.

Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy
Scheiner B, Kang B, Balcar L, Radu I, Reiter F, Adžić G, Guo J, Gao X, Yuan X, Cheng L, Gorgulho J, Schultheiss M, Peeters F, Hucke F, Ben Khaled N, Piseddu I, Philipp A, Sinner F, D'Alessio A, Pomej K, Saborowski A, Bathon M, Schwacha-Eipper B, Zarka V, Lampichler K, Nishida N, Lee P, Krall A, Saeed A, Himmelsbach V, Tesini G, Huang Y, Vivaldi C, Masi G, Vogel A, Schulze K, Trauner M, Djanani A, Stauber R, Kudo M, Parikh N, Dufour J, Prejac J, Geier A, Bengsch B, von Felden J, Venerito M, Weinmann A, Peck-Radosavljevic M, Finkelmeier F, Dekervel J, Ji F, Wang H, Rimassa L, Pinato D, Bouattour M, Chon H, Pinter M
HEPATOLOGY. 2025;81(6):1714-1727.

Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis
Schulze K, Rose T, Adlung L, Peschka M, Pagani F, Gorgulho J, Fründt T, Labgaa I, Haber P, Zimpel C, Castven D, Weinmann A, Garzia-Lezana T, Waldmann M, Renné T, Voß H, Moritz M, Orlikowski D, Schlüter H, Baumbach J, Schwartz M, Lohse A, Huber S, Sangro B, Macias R, Izquierdo-Sanchez L, Banales J, Wege H, Marquardt J, Villanueva A, Pauling J, von Felden J
JHEP REP. 2025;7(5):101340.

2024

Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
Gorgulho J, Loosen S, Masood R, Giehren F, Pagani F, Buescher G, Kocheise L, Joerg V, Schmidt C, Schulze K, Roderburg C, Kinkel E, Fritzsche B, Wehmeyer S, Schmidt B, Kachel P, Rolling C, Götze J, Busch A, Sinn M, Pereira-Veiga T, Wikman H, Geffken M, Peine S, Matschl U, Altfeld M, Huber S, Lohse A, Beier F, Brümmendorf T, Bokemeyer C, Luedde T, von Felden J
J EXP CLIN CANC RES. 2024;43(1):298.

Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies
Gorgulho J, Roderburg C, Beier F, Bokemeyer C, Brümmendorf T, Loosen S, Luedde T
BRIT J CANCER. 2024;130(6):1013-1022.

Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients
Gorgulho J, von Felden J
ALIMENT PHARM THER. 2024;60(10):1467-1468.

2023

Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
Gorgulho J, Roderburg C, Beier F, Bokemeyer C, Brümmendorf T, Luedde T, Loosen S
FRONT IMMUNOL. 2023;14:1206953.

2021

Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies
Gorgulho J, Roderburg C, Heymann F, Schulze-Hagen M, Beier F, Vucur M, Kather J, Laleh N, Tacke F, Brümmendorf T, Luedde T, Loosen S
INT J CANCER. 2021;149(5):1189-1198.

Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy
Loosen S, Gorgulho J, Jördens M, Schulze-Hagen M, Beier F, Vucur M, Schneider A, Koppe C, Mertens A, Kather J, Tacke F, Keitel V, Brümmendorf T, Roderburg C, Luedde T
FRONT ONCOL. 2021;11:646883.

Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis
Loosen S, Schulze-Hagen M, Vucur M, Gorgulho J, Paffenholz P, Benz F, Mohr R, Demir M, Wree A, Kuhl C, Trautwein C, Tacke F, Bruners P, Luedde T, Roderburg C
JGH OPEN. 2021;5(3):356-363.

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
Loosen S, van den Bosch V, Gorgulho J, Schulze-Hagen M, Kandler J, Jördens M, Tacke F, Loberg C, Antoch G, Brümmendorf T, Neumann U, Kuhl C, Luedde T, Roderburg C
J CLIN MED. 2021;10(7):.

Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
Rolles B, Gorgulho J, Tometten M, Roderburg C, Vieri M, Abels A, Vucur M, Heymann F, Tacke F, Brümmendorf T, Luedde T, Beier F, Loosen S
FRONT ONCOL. 2021;11:729207.

Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies
Wirtz T, Loosen S, Schulze-Hagen M, Gorgulho J, Kandler J, Joerdens M, Demir M, Mohr R, Bruners P, Kuhl C, Trautwein C, Berres M, Tacke F, Luedde T, Roderburg C
CTS-CLIN TRANSL SCI. 2021;14(5):1853-1863.

2020

Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer
Loosen S, Breuer A, Tacke F, Kather J, Gorgulho J, Alizai P, Bednarsch J, Roeth A, Lurje G, Schmitz S, Brozat J, Paffenholz P, Vucur M, Ritz T, Koch A, Trautwein C, Ulmer T, Roderburg C, Longerich T, Neumann U, Luedde T
JHEP REP. 2020;2(2):.

Letzte Aktualisierung aus dem FIS: 31.08.2025 - 00:39 Uhr